Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria

Detalhes bibliográficos
Autor(a) principal: Gonçalves, Tiago
Data de Publicação: 2023
Outros Autores: Marques, Andreia T., Manageiro, Vera, Tanoeiro, Luis, Vital, Joana S., Duarte, Aida, Vítor, Jorge M.B., Caniça, Manuela, Gaspar, Maria Manuela, Vale, Filipa F.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.18/8983
Resumo: Enterobacteriaceae species are part of the 2017 World Health Organization antibiotic-resistant priority pathogens list for development of novel medicines. Multidrug-resistant Klebsiella pneumoniae is an increasing threat to public health and has become a relevant human pathogen involved in life-threatening infections. Phage therapy involves the use of phages or their lytic endolysins as bioagents for the treatment of bacterial infectious diseases. Gram-negative bacteria have an outer membrane, making difficult the access of endolysins to the peptidoglycan. Here, three endolysins from prophages infecting three distinct Enterobacterales species, Kp2948-Lys from K. pneumoniae, Ps3418-Lys from Providencia stuartii, and Kaer26608-Lys from Klebsiella aerogenes, were purified and exhibited antibacterial activity against their specific bacterium species verified by zymogram assays. These three endolysins were successfully associated to liposomes composed of dimyristoyl phosphatidyl choline (DMPC), dioleoyl phosphatidyl ethanolamine (DOPE) and cholesteryl hemisuccinate (CHEMS) at a molar ratio (4:4:2), with an encapsulation efficiency ranging from 24 to 27%. Endolysins encapsulated in liposomes resulted in higher antibacterial activity compared to the respective endolysin in the free form, suggesting that the liposome-mediated delivery system enhances fusion with outer membrane and delivery of endolysins to the target peptidoglycan. Obtained results suggest that Kp2948-Lys appears to be specific for K. pneumoniae, while Ps3418-Lys and Kaer26608-Lys appear to have a broader antibacterial spectrum. Endolysins incorporated in liposomes constitute a promising weapon, applicable in the several dimensions (human, animals and environment) of the One Health approach, against multidrug-resistant Enterobacteriaceae.
id RCAP_cee1fd10b4c74556e300ae0521a2302c
oai_identifier_str oai:repositorio.insa.pt:10400.18/8983
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteriaAntibiotic ResistanceEndolysinEndolysinEnterobacteriaceaeKlebsiella pneumoniaeLiposomePhage TherapyResistência aos AntimicrobianosEnterobacteriaceae species are part of the 2017 World Health Organization antibiotic-resistant priority pathogens list for development of novel medicines. Multidrug-resistant Klebsiella pneumoniae is an increasing threat to public health and has become a relevant human pathogen involved in life-threatening infections. Phage therapy involves the use of phages or their lytic endolysins as bioagents for the treatment of bacterial infectious diseases. Gram-negative bacteria have an outer membrane, making difficult the access of endolysins to the peptidoglycan. Here, three endolysins from prophages infecting three distinct Enterobacterales species, Kp2948-Lys from K. pneumoniae, Ps3418-Lys from Providencia stuartii, and Kaer26608-Lys from Klebsiella aerogenes, were purified and exhibited antibacterial activity against their specific bacterium species verified by zymogram assays. These three endolysins were successfully associated to liposomes composed of dimyristoyl phosphatidyl choline (DMPC), dioleoyl phosphatidyl ethanolamine (DOPE) and cholesteryl hemisuccinate (CHEMS) at a molar ratio (4:4:2), with an encapsulation efficiency ranging from 24 to 27%. Endolysins encapsulated in liposomes resulted in higher antibacterial activity compared to the respective endolysin in the free form, suggesting that the liposome-mediated delivery system enhances fusion with outer membrane and delivery of endolysins to the target peptidoglycan. Obtained results suggest that Kp2948-Lys appears to be specific for K. pneumoniae, while Ps3418-Lys and Kaer26608-Lys appear to have a broader antibacterial spectrum. Endolysins incorporated in liposomes constitute a promising weapon, applicable in the several dimensions (human, animals and environment) of the One Health approach, against multidrug-resistant Enterobacteriaceae.F.F.V. was funded by Fundação para a Ciência e a Tecnologia (FCT) through a project grant (PTDC/BTM-SAL/28978/2017) that supported this work. The work is partially supported by National funds from FCT, projects UIDB/04138/2020, UIDP/04138/2020, UIDB/00211/2020 and UIDB/04046/2020 (DOI https://doi.org/10.54499/UIDB/0404 6/2020)ElsevierRepositório Científico do Instituto Nacional de SaúdeGonçalves, TiagoMarques, Andreia T.Manageiro, VeraTanoeiro, LuisVital, Joana S.Duarte, AidaVítor, Jorge M.B.Caniça, ManuelaGaspar, Maria ManuelaVale, Filipa F.2024-01-25T12:33:26Z2023-12-302023-12-30T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/8983engInt J Pharm. 2023 Dec 30:651:123758. doi: 10.1016/j.ijpharm.2023.123758. Online ahead of print.0378-517310.1016/j.ijpharm.2023.123758info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-01-27T01:32:28Zoai:repositorio.insa.pt:10400.18/8983Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T01:58:01.229640Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria
title Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria
spellingShingle Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria
Gonçalves, Tiago
Antibiotic Resistance
Endolysin
Endolysin
Enterobacteriaceae
Klebsiella pneumoniae
Liposome
Phage Therapy
Resistência aos Antimicrobianos
title_short Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria
title_full Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria
title_fullStr Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria
title_full_unstemmed Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria
title_sort Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria
author Gonçalves, Tiago
author_facet Gonçalves, Tiago
Marques, Andreia T.
Manageiro, Vera
Tanoeiro, Luis
Vital, Joana S.
Duarte, Aida
Vítor, Jorge M.B.
Caniça, Manuela
Gaspar, Maria Manuela
Vale, Filipa F.
author_role author
author2 Marques, Andreia T.
Manageiro, Vera
Tanoeiro, Luis
Vital, Joana S.
Duarte, Aida
Vítor, Jorge M.B.
Caniça, Manuela
Gaspar, Maria Manuela
Vale, Filipa F.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Nacional de Saúde
dc.contributor.author.fl_str_mv Gonçalves, Tiago
Marques, Andreia T.
Manageiro, Vera
Tanoeiro, Luis
Vital, Joana S.
Duarte, Aida
Vítor, Jorge M.B.
Caniça, Manuela
Gaspar, Maria Manuela
Vale, Filipa F.
dc.subject.por.fl_str_mv Antibiotic Resistance
Endolysin
Endolysin
Enterobacteriaceae
Klebsiella pneumoniae
Liposome
Phage Therapy
Resistência aos Antimicrobianos
topic Antibiotic Resistance
Endolysin
Endolysin
Enterobacteriaceae
Klebsiella pneumoniae
Liposome
Phage Therapy
Resistência aos Antimicrobianos
description Enterobacteriaceae species are part of the 2017 World Health Organization antibiotic-resistant priority pathogens list for development of novel medicines. Multidrug-resistant Klebsiella pneumoniae is an increasing threat to public health and has become a relevant human pathogen involved in life-threatening infections. Phage therapy involves the use of phages or their lytic endolysins as bioagents for the treatment of bacterial infectious diseases. Gram-negative bacteria have an outer membrane, making difficult the access of endolysins to the peptidoglycan. Here, three endolysins from prophages infecting three distinct Enterobacterales species, Kp2948-Lys from K. pneumoniae, Ps3418-Lys from Providencia stuartii, and Kaer26608-Lys from Klebsiella aerogenes, were purified and exhibited antibacterial activity against their specific bacterium species verified by zymogram assays. These three endolysins were successfully associated to liposomes composed of dimyristoyl phosphatidyl choline (DMPC), dioleoyl phosphatidyl ethanolamine (DOPE) and cholesteryl hemisuccinate (CHEMS) at a molar ratio (4:4:2), with an encapsulation efficiency ranging from 24 to 27%. Endolysins encapsulated in liposomes resulted in higher antibacterial activity compared to the respective endolysin in the free form, suggesting that the liposome-mediated delivery system enhances fusion with outer membrane and delivery of endolysins to the target peptidoglycan. Obtained results suggest that Kp2948-Lys appears to be specific for K. pneumoniae, while Ps3418-Lys and Kaer26608-Lys appear to have a broader antibacterial spectrum. Endolysins incorporated in liposomes constitute a promising weapon, applicable in the several dimensions (human, animals and environment) of the One Health approach, against multidrug-resistant Enterobacteriaceae.
publishDate 2023
dc.date.none.fl_str_mv 2023-12-30
2023-12-30T00:00:00Z
2024-01-25T12:33:26Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.18/8983
url http://hdl.handle.net/10400.18/8983
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Int J Pharm. 2023 Dec 30:651:123758. doi: 10.1016/j.ijpharm.2023.123758. Online ahead of print.
0378-5173
10.1016/j.ijpharm.2023.123758
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137065703571456